SALES FORECAST OF TOP PHARMACEUTICALS IN 2021
Nature Reviews Drug Discovery and Evaluate Pharma published the 2021 sales forecast of best-selling drugs.
Also read: The US Healthcare System
Humira is expected to remain the best-selling product, driving the sales of AbbVie. The product has been facing biosimilar competition in Europe, but the US market was primarily driving the sales. Nearly 80% of the Humira sales are being generated in the US, where the product will face biosimilar competition from 2023.
Also read: Japan Healthcare System
Merck’s Keytruda sales are expected to touch $16.8 billion. Keytruda, a PD-L1 inhibitor, is expected to have almost twice the revenues of Opdivo, another PD-L1 inhibitor. The product is approved for nearly 15 indications in the US, and the sales are primarily driven because of the lung cancer indication. The product is contributing to almost 30% of Merck’s revenues.
BMS obtained Revlimid with the acquisition of Celgene. The product is expected to add $12.71 billion to BMS in 2021. However, the product will face generic competition in the US market from 2022. The company has recently settled patent litigation with Cipla.
Also read: The US healthcare system
Eliquis, a product indicated for preventing stroke/systemic embolism in patients with NVAF and treatment of DVT/PE, is anticipated to forth the best-selling product in 2021.
Also read: Japan healthcare system
Eylea, a product indicated for treating various eye diseases (wet age-related macular degeneration, visual impairment due to diabetic macular edema, and myopic choroidal neovascularization), might become the fifth best selling product in 2021. The product has higher sales than the Lucentis, a Roche product indicated for the same indications.
Also read: Healthcare system in Italy